https://www.selleckchem.com/products/c75.html
n India. Systematic Review Registration https//clinicaltrials.gov, identifier [CRD42019141037].Antimicrobial resistance in Neisseria gonorrhoeae is threatening the treatment and control of gonorrhea globally, and new treatment options are imperative. Utilizing our dynamic in vitro hollow fiber infection model (HFIM), we examined the pharmacodynamics of the first-in-class spiropyrimidinetrione (DNA gyrase B inhibitors), zoliflodacin, against the N. gonorrhoeae reference strains World Health Organization F (susceptible to all relevant antimic
Aimer
Commentaire
Partagez
